News

Barr is likely to face competition for the capture of Pliva, eastern Europe’s biggest drug maker, as the entire generics industry heads towards greater consolidation. After having an

Vical retains exclusive marketing rights for the drug in the US and the rest of the world outside of specified Asian countries, for which AnGes received exclusive rights.

Biogen Idec licensed the exclusive worldwide rights to develop and market BG-12 from Swiss based privately held pharmaceutical company Fumapharm. The study achieved its primary endpoint, demonstrating that

This clinical trial is designed to assess the safety and efficacy of velafermin for the prevention of oral mucositis in cancer patients receiving high-dose chemotherapy, with or without

The “cooperative research and development agreement” (CRADA) will provide Lentigen with access to Edgewood Chemical Biological Center's (ECBC) manufacturing facilities and services. Financial terms of the deal were

A twice-daily formulation of Xibrom has already been approved by the FDA for the indication. The Xibrom once-daily phase III clinical trials are expected to enroll approximately 350

The trial is being conducted by Cancer and Leukemia Group B (CALGB), an oncology clinical research group sponsored by the National Cancer Institute (NCI). LE-SN38 is NeoPharm's NeoLipid

Oracea is the first FDA-approved, orally-administered, systemically-delivered drug to treat rosacea, a dermatologic condition that affects an estimated 14 million adults in the US. CollaGenex said that it

The agreement allows Isis to sell registered shares of its common stock at a small discount to the market price to Azimuth Opportunity over the next 18 months.